Double attack on EGFR-Positive tumors: targeted drug plus immunotherapy combo tested
NCT ID NCT07712029
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This phase II trial tests a combination of two drugs—becotatug vedotin, which targets cancer cells with high levels of EGFR, and pucotenlimab, which helps the immune system attack tumors—in people with advanced solid tumors that have not responded to standard treatments. The study aims to see how well the combination shrinks tumors and how safe it is. About 32 participants will receive both drugs intravenously every three weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of two drugs: becotatug vedotin (an antibody-drug conjugate targeting EGFR) and pucotenlimab (an immunotherapy that blocks PD-1)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced solid tumors that have high levels of EGFR and have stopped responding to standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 32 participants, so results may not apply broadly. The combination may cause significant side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED REFRACTORY SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical Unversity Second Hospital
RECRUITINGTianjin, Tianjin Municipality, 300211, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.